Clinical Trial Update: Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of Vyxeos (CPX-351) in adults with relapsed or refractory acute lymphoblastic leukemia has completed and results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Vyxeos (CPX-351)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Lymphoid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2022-07-14